Bladder Cancer Clinical Trial
Official title:
PK Button Vaporization Electrode for Treatment of Bladder Tumors
The purpose of this study is to compare the use of two types of equipment during transurethral resection of bladder tumors (TURBT). The two types of surgical devices are: the monopolar loop electrocautery and the PlasmaKinetic (PK) Button Vaporization Electrode. These two devices do the same task but differ in the way they create electric current when removing cancerous tissue. The investigators hope to examine and compare the uses of these two surgical devices to see if any advantages do exist or whether they actually are similar. The goal of the study is to prove similarity in outcomes between the two techniques and analyze the outcomes resulting from each case.
This study will study the medical intervention used when bladder cancer patients present with
a new or recurrent bladder tumor. Currently when patients report these tumors, they undergo a
standard practice called transurethral resection of the bladder tumor (TURBT) in order to
determine the stage of the cancer. This intervention, accomplished by looking through the
urethra using an endoscope, is both diagnostic and potentially therapeutic. An adequately
performed TURBT will provide the pathologist with enough tissue to provide tumor grade and
stage information. Currently, TURBT is done using equipment called monopolar electrocautery
which is in the form a 90-degree loop electrode. Although usually safe and sufficient, this
technique can create technical challenges because it can be difficult to position the loop
electrode in a dynamically changing cylindrical space (the bladder). Specifically, especially
with larger bladder tumors, intraoperative bleeding can obscure visualization and result in
incomplete tumor resection as well as inadequate sampling of the layers of the bladder needed
to establish tumor stage. Furthermore, monopolar current can result in stimulation of a nerve
(the obturator nerve) during resection of wall tumors, resulting in violent movement of the
leg which can cause a potential bladder tear as well as possible (iliac) vessel injury.
Conversely, a technique using bipolar energy, which has been available for many years, has
been readily adopted for the surgical treatment of benign prostatic enlargement. The
advantages of a bipolar electrical current include the direct return of electrical current to
the loop rather than to a grounding pad placed on the patient's skin. This has the
theoretical value of limiting the diffusion of electrical current, and therefore heat, to the
surrounding tissue. A further refinement on bipolar energy has been the recent introduction
of a piece of equipment called the PlasmaKinetic (PK) Button Vaporization electrode, which is
currently approved by the Food and Drug Administration (FDA) for this indication. Coupling
bipolar energy into the Button electrode would not only harness the benefits of less thermal
spread but also would obviate the geometric challenges associated with loop electrodes during
resection of bladder tumors. Procedural advantages would potentially include minimal
bleeding, good visualization, and a reduction in the occurrence of the obturator reflex and
concomitant bladder perforation.
This study is a randomized double-arm trial examining the results of both techniques for
bladder cancer TURBT procedures with a minimum of 120 patients at Emory. The purpose of this
study is to measure the procedural (intraoperative), short term, as clinically indicated (4-6
weeks), and long-term (3 months) outcomes of TURBT using the PK Button when compared to
traditional monopolar loop electrocautery. The goal of the study is to prove equivalence in
outcomes between the two techniques.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06034015 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04235764 -
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
|
||
Completed |
NCT02371447 -
VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04081246 -
Transurethral Modified En Bloc Resection For Large Bladder Tumours.
|
N/A | |
Recruiting |
NCT06059547 -
Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
|
Phase 2 | |
Terminated |
NCT04779489 -
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
|
N/A | |
Not yet recruiting |
NCT04493489 -
Propranolol Adjuvant Treatment of Bladder Cancer
|
Phase 2 | |
Completed |
NCT03520231 -
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
|
Phase 2 | |
Recruiting |
NCT04537221 -
Nordic Cystectomy Study III - Transfusion
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05562791 -
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer
|
Phase 1 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT02781428 -
To Detect the Sensitivity of the UroMark Assay
|
||
Recruiting |
NCT04738630 -
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03978624 -
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
|
Phase 2 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A |